Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma:
Biomarkers and functional imaging
#MMPMID26380650
Bouattour M
; Payancé A
; Wassermann J
World J Hepatol
2015[Sep]; 7
(20
): 2245-63
PMID26380650
show ga
Many years after therapeutic wilderness, sorafenib finally showed a clinical
benefit in patients with advanced hepatocellular carcinoma. After the primary
general enthusiasm worldwide, some disappointments emerged particularly since no
new treatment could exceed or at least match sorafenib in this setting. Without
these new drugs, research focused on optimizing care of patients treated with
sorafenib. One challenging research approach deals with identifying prognostic
and predictive biomarkers of sorafenib in this population. The task still seems
difficult; however appropriate investigations could resolve this dilemma, as
observed for some malignancies where other drugs were used.
free
free
free
